(Q38182650)

30 August 2017

title

EFNS/ENS Guidelines for the treatment of ocular myasthenia (English)

1 reference

30 August 2017

5

N E Gilhus

1 reference

30 August 2017

E Kerty

1

1 reference

30 August 2017

A Elsais

series ordinal

2

1 reference

30 August 2017

Z Argov

series ordinal

3

1 reference

30 August 2017

A Evoli

series ordinal

4

1 reference

30 August 2017

publication date

28 January 2014

1 reference

European Journal of Neurology

30 August 2017

published in

1 reference

30 August 2017

volume

21

1 reference

30 August 2017

issue

5

1 reference

30 August 2017

page(s)

687-693

1 reference

Guidelines for treatment of autoimmune neuromuscular transmission disorders

30 August 2017

cites work

1 reference

Safety of prednisone for ocular myasthenia gravis.

21 January 2018

1 reference

The course of myasthenia gravis and therapies affecting outcome

21 January 2018

1 reference

Treatment of ocular myasthenia gravis

21 January 2018

1 reference

Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays

21 January 2018

1 reference

Acetylcholine receptor expression in human extraocular muscles and their susceptibility to myasthenia gravis

21 January 2018

1 reference

Ocular myasthenia gravis: response to long-term immunosuppressive treatment

21 January 2018

1 reference

Anti-MuSK myasthenia gravis presenting with purely ocular findings

21 January 2018

1 reference

Ocular involvement in MuSK antibody-positive myasthenia gravis

21 January 2018

1 reference

Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis.

21 January 2018

1 reference

Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis

21 January 2018

1 reference

Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis.

21 January 2018

1 reference

Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects

21 January 2018

1 reference

Ocular Aspects of Myasthenia Gravis

21 January 2018

1 reference

Quantitative ocular tests for myasthenia gravis: a comparative review with detection theory analysis

21 January 2018

1 reference

Development of generalized disease at 2 years in patients with ocular myasthenia gravis

21 January 2018

1 reference

Glucocorticoids in T cell apoptosis and function.

21 January 2018

1 reference

Glucocorticoid modulation of cytokine signaling

21 January 2018

1 reference

Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment

21 January 2018

1 reference

Does early treatment of ocular myasthenia gravis with prednisone reduce progression to generalized disease?

21 January 2018

1 reference

Treatment of ocular myasthenia with corticosteroids: yes.

21 January 2018

1 reference

Beneficial effects of corticosteroids on ocular myasthenia gravis.

21 January 2018

1 reference

Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients.

21 January 2018

1 reference

Long-term outcomes of pediatric ocular myasthenia gravis

21 January 2018

1 reference

Treatment of ocular symptoms in myasthenia gravis

21 January 2018

1 reference

Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up

21 January 2018

1 reference

Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis

21 January 2018

1 reference

The effect of prednisone on the progression from ocular to generalized myasthenia gravis

21 January 2018

1 reference

Development of Generalized Myasthenia Gravis in Patients With Ocular Myasthenia Gravis

21 January 2018

1 reference

The mosaic of immunosuppressive drugs.

21 January 2018

1 reference

A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group

21 January 2018

1 reference

Azathioprine, Mycophenolate Mofetil, and Methotrexate Specifically Modulate Cytokine Production by T Cells

21 January 2018

1 reference

Mycophenolate mofetil for ocular myasthenia

21 January 2018

1 reference

Mycophenolate Mofetil for Myasthenia Gravis A Double‐Blind, Placebo‐Controlled Pilot Study

21 January 2018

1 reference

Tacrolimus monotherapy: a promising option for ocular myasthenia gravis.

21 January 2018

1 reference

A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis

21 January 2018

1 reference

Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

Treatment and outcome of myasthenia gravis: retrospective multi-center analysis of 470 Japanese patients, 1999–2000

21 January 2018

1 reference

Extended transsternal thymectomy for the treatment of ocular myasthenia gravis

21 January 2018

1 reference

Thymectomy in myasthenia with pure ocular symptoms

21 January 2018

1 reference

Thymectomy in the treatment of ocular myasthenia gravis

21 January 2018

1 reference

Outcomes after thymectomy in class I myasthenia gravis

21 January 2018

1 reference

Silicone frontalis slings for the correction of blepharoptosis: indications and efficacy.

21 January 2018

1 reference

Orthoptic indications for contact lens wear

21 January 2018

1 reference

Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/ENE.12359

1 reference

30 August 2017

1 reference